KORU Medical Systems Reports Record Q4 & FY25 Revenue, Achieves Full Year Positive Operating Cash Flow
Summary
KORU Medical Systems reported preliminary record revenue for Q4 and full year 2025, alongside achieving positive operating cash flow for the full year, signaling strong operational performance and financial health.
Key Events
-
Record Revenue Growth
Preliminary Q4 2025 net revenues reached $10.9 million, representing 23% growth over the prior year period. Full year 2025 net revenues were $41.1 million, a 22% increase year-over-year.
-
Achieves Positive Operating Cash Flow
The company achieved positive operating cash flow for the full year 2025, ending with an $8.9 million cash balance, demonstrating improved financial health.
-
Strategic Expansion Progress
CEO Linda Tharby highlighted continued strength in the core immunoglobulin business, progress in international expansion, and a key 510(k) submission for the Freedom Infusion System for use with Phesgo®, indicating expansion into oncology.
Analysis
KORU Medical Systems announced strong preliminary financial results for Q4 and the full year 2025, highlighted by record revenue growth and the significant achievement of positive operating cash flow for the full year. This indicates improved operational efficiency and financial stability, positioning the company for continued growth. The company also noted progress in international expansion and a key 510(k) submission, signaling strategic execution beyond its core business.
At the time of this filing, KRMD was trading at $5.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $255.3M. The 52-week trading range was $1.86 to $6.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.